CHEBI:134689 - rucaparib

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name rucaparib
ChEBI ID CHEBI:134689
Definition A member of the class of azepinoindoles that is 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one carrying additional 4-[(methylamino)methyl]phenyl and fluoro substituents at positions 2 and 8 respectively. It is an inhibitor of poly (ADP-ribose) polymerase and is used (as the camsylate salt) as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation.
Stars This entity has been manually annotated by the ChEBI Team.
Secondary ChEBI IDs CHEBI:94311
Supplier Information
Download Molfile XML SDF
more structures >>
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C19H18FN3O
Net Charge 0
Average Mass 323.371
Monoisotopic Mass 323.14339
InChI InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
InChIKey HMABYWSNWIZPAG-UHFFFAOYSA-N
SMILES CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
An EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of a NAD+ ADP-ribosyltransferase (EC 2.4.2.30).
Application(s): antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing rucaparib (CHEBI:134689) has role antineoplastic agent (CHEBI:35610)
rucaparib (CHEBI:134689) has role EC 2.4.2.30 (NAD+ ADP-ribosyltransferase) inhibitor (CHEBI:62913)
rucaparib (CHEBI:134689) is a azepinoindole (CHEBI:134691)
rucaparib (CHEBI:134689) is a caprolactams (CHEBI:23000)
rucaparib (CHEBI:134689) is a organofluorine compound (CHEBI:37143)
rucaparib (CHEBI:134689) is a secondary amino compound (CHEBI:50995)
rucaparib (CHEBI:134689) is conjugate base of rucaparib(1+) (CHEBI:134695)
Incoming rucaparib(1+) (CHEBI:134695) is conjugate acid of rucaparib (CHEBI:134689)
IUPAC Name
8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
INNs Sources
rucaparib WHO MedNet
rucaparib WHO MedNet
rucaparib WHO MedNet
rucaparibum WHO MedNet
Synonym Source
AG-14447 ChemIDplus
Manual Xrefs Databases
8107584 ChemSpider
D10079 KEGG DRUG
DB12332 DrugBank
LSM-4947 LINCS
RPB PDBeChem
Rucaparib Wikipedia
View more database links
Registry Numbers Types Sources
11556434 Reaxys Registry Number Reaxys
283173-50-2 CAS Registry Number KEGG DRUG
283173-50-2 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
24900770 PubMed citation Europe PMC
25689628 PubMed citation Europe PMC
26438157 PubMed citation Europe PMC
27002934 PubMed citation Europe PMC
27087632 PubMed citation Europe PMC
27128213 PubMed citation Europe PMC
27228289 PubMed citation Europe PMC
27415012 PubMed citation Europe PMC
27515310 PubMed citation Europe PMC
27600766 PubMed citation Europe PMC
27702817 PubMed citation Europe PMC
27716873 PubMed citation Europe PMC
27866910 PubMed citation Europe PMC
27908594 PubMed citation Europe PMC
27940438 PubMed citation Europe PMC
28001384 PubMed citation Europe PMC
28057616 PubMed citation Europe PMC
28069724 PubMed citation Europe PMC
28205191 PubMed citation Europe PMC
28790837 PubMed citation Europe PMC
30830551 PubMed citation Europe PMC
30977683 PubMed citation Europe PMC
32121331 PubMed citation Europe PMC
32173049 PubMed citation Europe PMC
32241924 PubMed citation Europe PMC
32495160 PubMed citation Europe PMC
32717310 PubMed citation Europe PMC
32795228 PubMed citation Europe PMC
33053351 PubMed citation Europe PMC
33145877 PubMed citation Europe PMC
33332934 PubMed citation Europe PMC
33343988 PubMed citation Europe PMC
33369704 PubMed citation Europe PMC
33515503 PubMed citation Europe PMC
33752918 PubMed citation Europe PMC
33780687 PubMed citation Europe PMC
Last Modified
08 April 2021